Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 8846784 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Ben-Levy R, et al. (1995) Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J 14, 5920-30 8846784
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S9-p - MAPKAPK2 (human)
Orthologous residues
MAPKAPK2 (human): S9‑p, MAPKAPK2 (mouse): T9‑p, MAPKAPK2 (rat): T9‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)

T25-p - MAPKAPK2 (human)
Orthologous residues
MAPKAPK2 (human): T25‑p, MAPKAPK2 (mouse): S16‑p, MAPKAPK2 (rat): S16‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
arsenite increase
SB203580 arsenite inhibit treatment-induced increase

T222-p - MAPKAPK2 (human)
Orthologous residues
MAPKAPK2 (human): T222‑p, MAPKAPK2 (mouse): T208‑p, MAPKAPK2 (rat): T208‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
KINASE P38A (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
arsenite increase
SB203580 arsenite inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced

S272-p - MAPKAPK2 (human)
Orthologous residues
MAPKAPK2 (human): S272‑p, MAPKAPK2 (mouse): S258‑p, MAPKAPK2 (rat): S258‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE P38A (human)
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
arsenite increase
SB203580 arsenite inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced

T334-p - MAPKAPK2 (human)
Orthologous residues
MAPKAPK2 (human): T334‑p, MAPKAPK2 (mouse): T320‑p, MAPKAPK2 (rat): T320‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE P38A (human)
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
arsenite increase
SB203580 arsenite inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced

T338-p - MAPKAPK2 (human)
Orthologous residues
MAPKAPK2 (human): T338‑p, MAPKAPK2 (mouse): T324‑p, MAPKAPK2 (rat): T324‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MAPKAPK2 (human)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.